Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin

ConclusionsEfficacy and safety (including immunogenicity) profiles of SAR-Asp are similar to those of NN-Asp over 52 weeks in adults with diabetes irrespective of prior type of mealtime insulin.Trial RegistrationClinicalTrials.gov identifier: NCT03211858.

http://link.springer.com/10.1007/s13300-020-00992-x

Source: Diabetes Therapy - January 11, 2021 Category: Endocrinology Source Type: research